Rendering of the new build in Hamilton, Ontario. (Credit: OmniaBio)
October 17, 2024 08:00 AM EDTUpdated 08:20 AM
Manufacturing

Cana­di­an CD­MO broad­ens CGT foot­print with new $145M fa­cil­i­ty 

Anna Brown

News Reporter

CD­MO Om­ni­aBio on Thurs­day opened a com­mer­cial-stage cell man­u­fac­tur­ing fa­cil­i­ty that has AI ca­pa­bil­i­ties worth around CAD $200 mil­lion ($145 mil­lion) in its home­town of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

A service from the Financial Times